Form 4: Adverum Biotechnologies Director Soo Hong Granted Stock Options

Adverum Biotechnologies, Inc. Director Soo Hong was granted 10,450 stock options with an exercise price of $2.32, aligning executive incentives with shareholder interests.

Summary

• Soo Hong, a Director of Adverum Biotechnologies, Inc. (ADVM), was granted 10,450 stock options.
• The stock options have an exercise price of $2.32 per share.
• The grant date for these options was June 17, 2025.
• The options will vest and become exercisable on the earlier of June 17, 2026, or the 2026 annual meeting of stockholders.
• Vesting is contingent upon Mr. Hong's continued service with the Issuer on the vesting date.
• Accelerated vesting will occur upon a change of control of the company.
• The expiration date for these stock options is June 16, 2035.
• Following this transaction, Mr. Hong beneficially owns 10,450 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a Form 4 is primarily a factual disclosure, the grant of stock options to a director is generally viewed positively as it aligns management's interests with shareholders, promoting long-term value creation. There are no negative disclosures.

Positives

• The grant of stock options to Director Soo Hong aligns his financial interests with those of the shareholders, incentivizing long-term company performance.
• The vesting schedule, tied to continued service, promotes stability in the company's governance.

Future Outlook

The stock options granted to Director Soo Hong are subject to future vesting conditions, specifically continued service with Adverum Biotechnologies until June 17, 2026, or the 2026 annual meeting of stockholders, whichever is earlier. Accelerated vesting is also possible upon a change of control.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity transaction, common across all publicly traded companies, including those in the biotechnology sector. It reflects a standard practice of compensating directors with equity to align their interests with long-term shareholder value.

Related Party Transactions

• The grant of stock options to Soo Hong, a Director of Adverum Biotechnologies, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of stock options to a director can be seen as a positive for shareholders, as it aligns the director's financial incentives with the company's long-term performance and shareholder value creation.

Next Steps

• The stock options will vest and become exercisable on the earlier of June 17, 2026, or the 2026 annual meeting of stockholders, provided the reporting person's continued service.

Key Dates

Keywords

Adverum Biotechnologies, ADVM, Stock Options, SEC Form 4, Insider Transaction, Director Compensation, Equity Grant, Biotechnology, Vesting